Closing the Loop in People With Type 1 Diabetes (CLEAR Phase 2)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05653050 |
Recruitment Status :
Not yet recruiting
First Posted : December 16, 2022
Last Update Posted : December 16, 2022
|
The main objective of this study is to determine whether home use of fully closed-loop glucose control applying age-approved ultra-rapid insulin (Phase 2) is superior to standard insulin pump therapy with continuous glucose monitoring (CGM) in adolescents with type 1 diabetes on insulin pump therapy with sub-optimal glycaemic control (HbA1c ≥ 7.5% [Phase 2]).
This is an open-label, multi-centre, randomised, crossover design study, involving a run-in period followed by two study periods during which glucose levels will be controlled either by an automated closed-loop system using age-approved ultra-rapid insulin or by participants' usual insulin pump therapy with continuous glucose monitoring in random order. A total of up to 30 adolescents (aiming for 24 completed participants) with T1D on insulin pump therapy will be recruited through diabetes clinics and other established methods.
Participants will receive appropriate training in the safe use of the closed-loop devices. Participants will have access to the study team during the home study phase with 24/7 telephone support.
The primary outcome is time spent in target range between 3.9 and 10.0 mmol/L as recorded by CGM over the 8 week period. Secondary outcomes are HbA1c, time spent with glucose levels above and below target as recorded by CGM, and other CGM-based metrics in addition to insulin requirements. Safety evaluation comprises severe hypoglycaemic episodes, diabetic ketoacidosis (DKA) events and other adverse and serious adverse events.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Type 1 Diabetes | Device: CamAPS HX Device: Standard insulin pump therapy with CGM | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 30 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Intervention Model Description: | An open-label, multi-centre, randomised, two-period, crossover study comparing fully closed-loop glucose control to standard insulin pump therapy combined with continuous glucose monitoring |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-label, Multi-centre, Randomised, Two-period, Crossover Study to Assess the Efficacy, Safety and Utility of Closed-loop Glucose Control Compared to Standard Insulin Pump Therapy Combined With Continuous Glucose Monitoring in Adolescents With Type 1 Diabetes |
Estimated Study Start Date : | January 4, 2023 |
Estimated Primary Completion Date : | January 4, 2024 |
Estimated Study Completion Date : | June 1, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: Fully closed-loop system with age-approved ultra-rapid insulin
The fully closed-loop system (CamAPS HX) will consist of:
Participants will use an age-approved ultra-rapid insulin in the closed-loop system. |
Device: CamAPS HX
Fully automated closed-loop system (CamAPS HX) with age-approved ultra-rapid insulin |
Active Comparator: Standard insulin pump therapy with CGM
Participants will use their own insulin pump and usual insulin throughout this study period. The CGM will be the Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA), or other compatible real-time CGM sensor. . |
Device: Standard insulin pump therapy with CGM
Participants usual insulin pump therapy with Dexcom G6 CGM |
- Time in target glucose range [ Time Frame: 8-week home use ]Time spent in the target glucose range from 3.9 to 10.0 mmol/l (70 to 180mg/dl) based on continuous glucose monitoring (CGM)
- Time spent above the target glucose range [ Time Frame: 8-week home use ]Time spent above target glucose (10.0 mmol/l) (180 mg/dl) based on CGM
- Time spent below the target glucose range [ Time Frame: 8-week home use ]Time spent below target glucose (3.9 mmol/l) (70 mg/dl) based on CGM
- Mean glucose [ Time Frame: 8-week home use ]Average of sensor glucose levels
- Standard deviation and coefficient of variation of glucose [ Time Frame: 8-week home use ]Standard deviation and coefficient of variation of CGM glucose levels
- Time spent in hypoglycaemia [ Time Frame: 8-week home use ]Time with glucose levels < 3.5 mmol/l (63mg/dl), < 3.0 mmol/l (54mg/dl), and <2.8 mmol/l (50mg/dl) based on CGM
- Time spent in hyperglycaemia [ Time Frame: 8-week home use ]Time with glucose levels in the significant hyperglycaemia (glucose levels > 20.0 mmol/l) (360mg/dl)
- HbA1c [ Time Frame: After 8-week home use ]Glycated haemoglobin measured at the end of the treatment period(360mg/dl)
- Total, basal, and bolus insulin dose [ Time Frame: 8-week home use ]Total, basal, and bolus insulin dose
- Safety evaluation [ Time Frame: 8-week home use ]The number of episodes of severe hypoglycaemia events
- Safety evaluation [ Time Frame: 8-week home use ]The number of episodes of DKA events
- Safety evaluation [ Time Frame: 8-week home use ]The number of episodes of significant ketonemia (> 3.0mmol/l) events
- Safety evaluation [ Time Frame: 8-week home use ]The number and nature of any other adverse events
- Safety evaluation [ Time Frame: 8-week home use ]The number of SADEs
- Utility evaluation [ Time Frame: 8-week home use ]Frequency and duration of use of the closed-loop system at home The number of episodes of hypoglycaemia, DKA and / or significant ketonemia (> 3.0mmol/l) as well as nature and severity of any other adverse events including SADEs and SAEs.
- Human Factor assessment [ Time Frame: After 8-week home use ]Expectations, attitudes and responses to the closed-loop system will be assessed using the INSPIRE questionnaire.
- Human Factor assessment [ Time Frame: After 8-week home use ]Diabetes distress will be assessed using the PAID-Teen questionnaire.
- Human Factor assessment [ Time Frame: After 8-week home use ]Hypoglycemia fear will be assessed using the Hypoglycemia Fear Survey (HFS II) Child version
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 13 Years to 19 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- The participant has type 1 diabetes as defined by WHO for at least 1 year
- The participant is aged 13 to 19 years (inclusive) (Phase 2)
- The participant will have been on an insulin pump for at least 3 months with good knowledge of insulin self-adjustment
- The participant is treated with one of the rapid acting or ultra-rapid acting insulin analogues (Insulin Aspart, faster acting insulin Aspart, Insulin Lispro, ultra-rapid Lispro insulin or Insulin Glulisine) 6. HbA1c ≥7.5% (58mmol/mol) based on analysis from local laboratory 7. The participant is willing to wear closed-loop devices 8. The participant is willing to follow study specific instructions 9. Female participants of child bearing age must have a negative urine-HCG pregnancy test at screening and should be using effective contraception if sexually active.
Exclusion Criteria:
- Any physical or psychological disease or condition likely to interfere with the normal conduct of the study and interpretation of the study results
- Known or suspected allergy against insulin
- Total daily insulin dose more than or equal to 2 IU/kg/day
- Use of a closed-loop system within the past 30 days
- Participant is pregnant or breast feeding or planning pregnancy within next 12 months
- Severe visual impairment
- Severe hearing impairment
- Lack of reliable telephone facility for contact
- Participant not proficient in English
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05653050
Contact: Julia Ware, MBChB | +441223769069 | jf674@cam.ac.uk |
Responsible Party: | Dr Roman Hovorka, Professor, University of Cambridge |
ClinicalTrials.gov Identifier: | NCT05653050 |
Other Study ID Numbers: |
CLEAR Phase 2 |
First Posted: | December 16, 2022 Key Record Dates |
Last Update Posted: | December 16, 2022 |
Last Verified: | December 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Study protocol, statistical analysis plan and fully anonymised individual participant data that underlie the results reported in the manuscript will be available 6 months following publication and ending 36 months following manuscript publication to investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose, to achieve aims in the approved proposal. Proposals should be directed to rh347@cam.ac.uk and may be submitted up to 36 months following article publication. To gain access, data requestors will need to sign a data access agreement. Fully anonymised data may be shared with third parties (EU or non-EU based) for the purposes of advancing management and treatment of diabetes. |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) |
Time Frame: | Study protocol, statistical analysis plan and fully anonymised individual participant data that underlie the results reported in the manuscript will be available 6 months following publication and ending 36 months following manuscript publication to investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose, to achieve aims in the approved proposal. Proposals should be directed to rh347@cam.ac.uk and may be submitted up to 36 months following article publication. |
Access Criteria: | Study protocol, statistical analysis plan and fully anonymised individual participant data that underlie the results reported in the manuscript will be available 6 months following publication and ending 36 months following manuscript publication to investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose, to achieve aims in the approved proposal. Proposals should be directed to rh347@cam.ac.uk and may be submitted up to 36 months following article publication. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Diabetes Mellitus Diabetes Mellitus, Type 1 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
Autoimmune Diseases Immune System Diseases Insulin Hypoglycemic Agents Physiological Effects of Drugs |